Jump Financial LLC Acquires New Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Jump Financial LLC purchased a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 154,842 shares of the company's stock, valued at approximately $1,075,000. Jump Financial LLC owned 0.25% of Monte Rosa Therapeutics as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GLUE. Versant Venture Management LLC purchased a new stake in Monte Rosa Therapeutics during the 4th quarter worth about $39,231,000. Vanguard Group Inc. raised its holdings in Monte Rosa Therapeutics by 24.5% during the fourth quarter. Vanguard Group Inc. now owns 3,156,354 shares of the company's stock worth $21,905,000 after purchasing an additional 622,134 shares in the last quarter. Norges Bank purchased a new stake in shares of Monte Rosa Therapeutics during the 4th quarter worth approximately $3,094,000. Geode Capital Management LLC boosted its holdings in shares of Monte Rosa Therapeutics by 23.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,044,689 shares of the company's stock valued at $5,538,000 after buying an additional 197,247 shares in the last quarter. Finally, AlphaQuest LLC acquired a new position in Monte Rosa Therapeutics in the fourth quarter valued at $657,000. Institutional investors and hedge funds own 79.96% of the company's stock.

Monte Rosa Therapeutics Stock Down 3.1 %

Shares of NASDAQ GLUE traded down $0.16 during mid-day trading on Friday, hitting $5.06. 392,635 shares of the company were exchanged, compared to its average volume of 1,048,160. The firm has a market cap of $311.24 million, a price-to-earnings ratio of -2.77 and a beta of 1.53. The stock has a 50 day simple moving average of $5.33 and a 200-day simple moving average of $6.56. Monte Rosa Therapeutics, Inc. has a 1-year low of $3.21 and a 1-year high of $12.40.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.60. The firm had revenue of $14.00 million during the quarter, compared to analyst estimates of $43.73 million. Analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Chandra P. Leo purchased 10,000 shares of the stock in a transaction dated Monday, March 24th. The shares were acquired at an average cost of $5.84 per share, with a total value of $58,400.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at $58,400. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GLUE. Wells Fargo & Company decreased their target price on Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating for the company in a research report on Friday, March 21st. Wedbush reiterated an "outperform" rating and issued a $17.00 price target (up previously from $15.00) on shares of Monte Rosa Therapeutics in a research report on Thursday, March 20th. Finally, Lifesci Capital initiated coverage on shares of Monte Rosa Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $19.00 price objective on the stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.